The Ohio State University Comprehensive Cancer Center (OSUCCC) is currently in its 35th year as an NCI designated CCC and is now requesting continued federal support for the next five years. Dr. Caligiuri currently continues in his seventh year as the OSUCCC Director and has since been named CEO of OSU's freestanding James Cancer Hospital. The overall goal remains to reduce cancer morbidity and mortality through continued basic, translational and clinical research. The 239 OSUCCC full, associate or introductory members are currently served by 18 shared resources and are distributed among the our six Research Programs which remain unchanged: Cancer Control, Experimental Therapeutics, Innate Immunity, Molecular Biology and Cancer Genetics, Molecular Carcinogenesis and Chemoprevention, and Viral Oncology. Since the last competitive renewal, the OSUCCC has shown significant growth as demonstrated by: 1) the recruitment of 159 faculty focused in basic, translational and clinical cancer research and medicine;2) more than a 80% increase in patient accrual to investigator-initiated trials;3) the addition of 5 new shared resources at an institutional investment of over $4.2 million;4) a 96% increase in total NCI funding despite a period of relatively flat federal funding;5) an 85% increase in publications, 51% of which were collaborative (i.e., inter-, intra-programmatic, or both);5) discovery, preclinical development and administration of two new anti-cancer agents into man, along with additional important advances in basic and clinical cancer research. The OSUCCC has also seen tremendous growth in institutional commitment since 2004 as demonstrated by 1) a ten-fold increase in annual financial support (now approximately $50 million) for the OSUCCC under the control of the Director;2) an additional $7.0 million of cash annually from OSU for research and infrastructure expansion;3) a formal direct reporting relationship to the Executive Vice President and Provost with complete oversight of the University-wide cancer funding initiatives, opportunities and cancer grant submissions;4) A seat on the University President's cabinet providing representation of the CCC at the highest level of the University;5) a six-fold increase in space currently under the sole control of the Director, including new additional dry and wet laboratory and office space for recruitment of additional faculty;6) a written commitment and approval by the OSU Board of Trustees for the expansion of the Cancer Program facilities that will more than double the current square footage under control of the OSUCCC Director in the next five years at a cost of approximately $800 million. With these new resource commitments in place, the OSUCCC is poised for continued significant growth and expansion in the next 5 years.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-35
Application #
8018783
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1997-09-12
Project End
2015-11-30
Budget Start
2011-08-05
Budget End
2011-11-30
Support Year
35
Fiscal Year
2011
Total Cost
$4,582,303
Indirect Cost
Name
Ohio State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
O'Brien, Susan M; Jaglowski, Samantha; Byrd, John C et al. (2018) Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. JAMA Oncol 4:712-716
Guo, Sijin; Piao, Xijun; Li, Hui et al. (2018) Methods for construction and characterization of simple or special multifunctional RNA nanoparticles based on the 3WJ of phi29 DNA packaging motor. Methods 143:121-133
Sadowski, Abbey R; Gardner, Heather L; Borgatti, Antonella et al. (2018) Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma. BMC Vet Res 14:250
Barredo, Julio C; Hastings, Caroline; Lu, Xiamin et al. (2018) Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. Pediatr Blood Cancer 65:e26928
Kim, So-Youn; Nair, Devi M; Romero, Megan et al. (2018) Transient inhibition of p53 homologs protects ovarian function from two distinct apoptotic pathways triggered by anticancer therapies. Cell Death Differ :
Yadav, Marshleen; Song, Feifei; Huang, Jason et al. (2018) Ocimum flavone Orientin as a countermeasure for thrombocytopenia. Sci Rep 8:5075
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
White, Brian S; Lanc, Irena; O'Neal, Julie et al. (2018) A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood Cancer J 8:35
Owen, Dwight; Chaft, Jamie E (2018) Immunotherapy in surgically resectable non-small cell lung cancer. J Thorac Dis 10:S404-S411
Barajas, Juan M; Reyes, Ryan; Guerrero, Maria J et al. (2018) The role of miR-122 in the dysregulation of glucose-6-phosphate dehydrogenase (G6PD) expression in hepatocellular cancer. Sci Rep 8:9105

Showing the most recent 10 out of 2602 publications